Full video transcriptClick to expand
Auto-generated transcript of @theblacklabelclinic's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00There is a peptide called CJC-1295,
- 0:03which is referred to as a GHRH,
- 0:06or growth hormone releasing hormone,
- 0:08because there's actually two versions of it.
- 0:10CJC-1295 with the DAC molecule,
- 0:14and there's CJC-1295 without the DAC molecule.
- 0:19First off, CJC-1295 has been shown
- 0:22to release growth hormone and IGF,
- 0:24in a rather large amount.
- 0:25So it's a very effective peptide.
- 0:27Many people say more effective than Simorlin.
- 0:30It's similar counterpart, but they just find it to be stronger.
- 0:32The difference between the two,
- 0:34the CJC-1295 with the DAC molecule,
- 0:38keeps it active in your bloodstream for about a week.
- 0:41Now, what that's going to do is cause the release
- 0:44of growth hormone over the entire week,
- 0:46through a pretty steady period,
- 0:47and then it'll start to taper down
- 0:48throughout the end of the week.
- 0:49The issue with that is our body
- 0:51does not naturally release growth hormone like that.
- 0:53It releases it in pulses throughout the day.
- 0:56Typically, the biggest pulse is around 1 a.m. over sleeping.
- 0:59The CJC-1295 without the DAC molecule
- 1:03is much more realistic in the sense
- 1:06that it follows our body's natural pulsing response.
- 1:09It's administered daily instead of once per week.
- 1:11So you do still get that natural GH pulse
- 1:14that up and down to mimic our body's natural response.
- 1:18The GH bleed, as it's referred to,
- 1:20where it goes over the entire week,
- 1:23does it mimic our body's natural response?
- 1:25So many people don't reap the same rewards
- 1:28as they would when they use the CJC without the DAC molecule.
- 1:33We want to mimic what our body does,
- 1:35or as close to what our body does naturally,
- 1:38for the best results.
- 1:39Both have been shown to be safe and effective,
- 1:41but the more effective version of the two
- 1:43is the CJC-1295 without the DAC molecule.
- 1:47So if you use that in conjunction with something like IPAM
- 1:50or Epimorlin or any of the GHRPs,
- 1:53you're going to get a fantastic result out of it
- 1:54more often than not,
- 1:56and it's a fraction of the cost of using HGH.
- 1:59In my opinion, I'm a big fan of it
- 2:01because if we can stimulate our body's natural response
- 2:04to produce more HGH and release it into our bloodstream,
- 2:06not only are we going to save a bunch of money,
- 2:08but our body will also not build up antibodies
- 2:10towards a foreign substance over a longer period of time,
- 2:13which in turn can require us to need to increase our GH dose.
Peptide therapy for gym gains: hype vs. what studies show
Quick answer
CJC-1295 is a synthetic GHRH analogue available in two forms distinguished by the presence or absence of a Drug Affinity Complex that extends its half-life from minutes to approximately 6-8 days. The creator's recommendation to prefer the non-DAC version for pulsatile GH mimicry aligns with a plausible physiological rationale, but head-to-head human clinical trial data comparing efficacy and safety outcomes between the two forms does not currently exist in peer-reviewed literature. Any use of CJC-1295 in either form requires physician oversight, baseline IGF-1 monitoring, and screening for contraindications including insulin resistance and active or suspected neoplasm.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide therapy for gym gains: hype vs. what studies show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide therapy for gym gains: hype vs. what studies show is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptide therapy for gym gains: hype vs. what studies show" from JUSTIN POLITIS. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: CJC-1295 is a synthetic GHRH analogue available in two forms distinguished by the presence or absence of a Drug Affinity Complex that extends its half-life from minutes to approximately 6-8 days.
The reason this review is not generic is the source wording and the canonical claim label "peptides hey guys i ll recommend you all try this out summer gymming." In this clip, the useful excerpt is: "There is a peptide called CJC-1295, which is referred to as a GHRH, or growth hormone releasing hormone, because there's actually two versions of it." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
CJC-1295 is a synthetic GHRH analogue available in two forms distinguished by the presence or absence of a Drug Affinity Complex that extends its half-life from minutes to approximately 6-8 days.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- CJC-1295 is a synthetic GHRH analogue available in two forms distinguished by the presence or absence of a Drug Affinity Complex that extends its half-life from minutes to approximately 6-8 days. The creator's recommendation to prefer the non-DAC version for pulsatile GH mimicry aligns with a plausible physiological rationale, but head-to-head human clinical trial data comparing efficacy and safety outcomes between the two forms does not currently exist in peer-reviewed literature. Any use of CJC-1295 in either form requires physician oversight, baseline IGF-1 monitoring, and screening for contraindications including insulin resistance and active or suspected neoplasm.
- Teichman et al. (2006, JCEM) is the primary human clinical trial for CJC-1295 with DAC, showing GH and IGF-1 elevation lasting up to 6 days. This is the core pharmacokinetic data supporting the 'week-long' half-life claim.
- CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes, which produces a shorter GH pulse. Published human clinical outcome data for this specific form is sparse compared to the DAC version.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Teichman et al. (2006, JCEM) is the primary human clinical trial for CJC-1295 with DAC, showing GH and IGF-1 elevation lasting up to 6 days. This is the core pharmacokinetic data supporting the 'week-long' half-life claim.
- CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes, which produces a shorter GH pulse. Published human clinical outcome data for this specific form is sparse compared to the DAC version.
- Neither CJC-1295 formulation is FDA-approved. Both exist in a compounding pharmacy regulatory context and require a licensed prescriber and ongoing lab monitoring including IGF-1 levels.
- Ipamorelin combined with a GHRH analogue is a recognized clinical protocol because GHRPs and GHRHs work on different receptor pathways. Combining them can produce additive GH release, but long-term safety studies in healthy adults are still limited.
- The claim that stimulating endogenous GH avoids antibody formation is physiologically inaccurate. Synthetic peptides carry documented immunogenicity risk and are not equivalent to the body's own endogenous GHRH.
- Growth hormone secretagogues are contraindicated in anyone with active or suspected malignancy, as GH and IGF-1 elevation can promote tumor growth. This is a non-negotiable screening requirement that no social media video can substitute for.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @theblacklabelclinic actually say?
The creator laid out a comparison between two versions of CJC-1295: one with the Drug Affinity Complex (DAC) molecule attached, one without. Their core argument is that CJC-1295 without DAC is superior because it mimics the body's natural pulsatile growth hormone release, while the DAC version causes a prolonged, steady release they call a "GH bleed" that works against your physiology. They also recommend stacking CJC-1295 without DAC alongside a GHRP like ipamorelin, and suggest this approach is both cheaper and safer long-term than exogenous HGH. That's a lot of claims packed into one short video, and some of them hold up better than others.
Does the science back this up?
The basic pharmacology here is largely accurate. CJC-1295 with DAC does produce a sustained elevation in growth hormone and IGF-1, while the version without DAC (sometimes marketed as "Modified GRF 1-29") produces shorter, more pulse-like elevations. Studies confirm both mechanisms work.
The foundational human clinical trial is Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism), which showed CJC-1295 with DAC produced dose-dependent increases in GH and IGF-1 lasting up to 6 days in healthy adults. That lines up with the creator's "about a week" figure. Research on GHRH analogues without DAC, including Modified GRF 1-29, is less extensive in peer-reviewed clinical literature, with much of the supporting evidence coming from preclinical or compounding-context sources rather than large randomized controlled trials. The claim that pulsatile release is categorically "better" is plausible physiologically but is not robustly proven in head-to-head human studies.
What did they get wrong (or right)?
They got the DAC pharmacology right. The distinction between sustained release and pulsatile release is real and scientifically grounded. Credit where it's due.
However, several claims need pushback. First, the assertion that "both have been shown to be safe and effective" overstates the evidence. CJC-1295 with DAC has one published human safety trial. CJC-1295 without DAC has very limited published human data. "Shown to be safe" is a regulatory and evidentiary standard, not just a community consensus from forums and clinics.
Second, the antibody argument, that using peptides to stimulate endogenous GH means "our body will not build up antibodies towards a foreign substance," is more complicated than presented. GHRH analogues are synthetic peptides. They are not endogenous molecules. Antibody responses to peptide therapeutics are well-documented in the literature (Krishna and Nadler, 2016, Journal of Immunology Research). This doesn't mean it's a dealbreaker, but presenting it as a clean safety advantage over exogenous HGH is an oversimplification.
Third, the comparison to "Simorlin" (sermorelin) is presented as community opinion, which is fair, but it's dressed up to sound like clinical consensus when it isn't.
What should you actually know?
Peptide-based growth hormone secretagogues are an active area of research, but most of what you hear in the peptide community is running well ahead of published clinical evidence. That gap matters, especially when these compounds are being sold and injected.
- Neither CJC-1295 with nor without DAC is FDA-approved for any indication. They exist in a regulatory gray zone, largely available through compounding pharmacies under prescriber oversight.
- The "pulsatile is better" argument is physiologically reasonable, but human outcome data comparing the two versions head-to-head does not exist in peer-reviewed literature as of this writing.
- If you are considering any growth hormone secretagogue, this is a conversation for a licensed clinician who can order baseline IGF-1 labs, assess contraindications (including active malignancy, where GH stimulation is a real concern), and monitor response.
- The cost comparison to exogenous HGH is accurate in general terms. Peptide secretagogues are typically far less expensive. But lower cost does not substitute for clinical evidence of equivalent outcomes.
- Ipamorelin stacking with CJC-1295 without DAC is a common clinical protocol. The combination has a rationale, but long-term safety data in healthy adults is still limited.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
JUSTIN POLITIS · TikTok creator
30.9K views on this video
Hey guys I'll recommend you all try this out . #summer #gymming
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about teichman et al. (2006, jcem)?
Teichman et al. (2006, JCEM) is the primary human clinical trial for CJC-1295 with DAC, showing GH and IGF-1 elevation lasting up to 6 days. This is the core pharmacokinetic data supporting the 'week-long' half-life claim.
What does the video say about cjc-1295 without dac (modified grf 1-29) has a half-life of?
CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes, which produces a shorter GH pulse. Published human clinical outcome data for this specific form is sparse compared to the DAC version.
What does the video say about neither cjc-1295 formulation?
Neither CJC-1295 formulation is FDA-approved. Both exist in a compounding pharmacy regulatory context and require a licensed prescriber and ongoing lab monitoring including IGF-1 levels.
What does the video say about ipamorelin combined with a ghrh analogue?
Ipamorelin combined with a GHRH analogue is a recognized clinical protocol because GHRPs and GHRHs work on different receptor pathways. Combining them can produce additive GH release, but long-term safety studies in healthy adults are still limited.
What does the video say about the claim?
The claim that stimulating endogenous GH avoids antibody formation is physiologically inaccurate. Synthetic peptides carry documented immunogenicity risk and are not equivalent to the body's own endogenous GHRH.
What does the video say about growth hormone secretagogues?
Growth hormone secretagogues are contraindicated in anyone with active or suspected malignancy, as GH and IGF-1 elevation can promote tumor growth. This is a non-negotiable screening requirement that no social media video can substitute for.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by JUSTIN POLITIS, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.